Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Nasopharyngeal Carcinoma 3Uterine Cervical Neoplasms 1Solid Tumors 1Sarcoma 1Nasopharyngeal Neoplasms 1Melanoma 1Esophageal Squamous Cell Carcinoma 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Specimen Handling 7Cisplatin 7pembrolizumab 6Nivolumab 4Magnetic Resonance Spectroscopy 4Human Papillomavirus DNA Tests 4Fulvestrant 4Colposcopy 4Paclitaxel 3Carboplatin 3Bevacizumab 3palbociclib 2lenvatinib 2Surveys and Questionnaires 2Radiotherapy, Intensity-Modulated 2Radiation Dose Hypofractionation 2Radiation 2Platinum 2Magnetic Resonance Imaging 2Gemcitabine 2Fluorodeoxyglucose F18 2Drug Therapy 2Congresses as Topic 2Brachytherapy 2Biopsy 2Axitinib 23-aminopyridine-2-carboxaldehyde thiosemicarbazone 21,2-diaminocyclohexaneplatinum II citrate 2ulixertinib 1trastuzumab deruxtecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uterine Cervical Neoplasms × spartalizumab × 30 days × Clear all
NCT07472153 2026-05-28

PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer

N.N. Alexandrov National Cancer Centre

Phase 2/3 Recruiting
120 enrolled
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡